Rapport Therapeutics Closes $172.5 Million Convertible Note Sale And $21.00-A-Share Stock Offering

The biotech also placed shares privately and estimated $395.0 million in cash at September 30, saying funds should last through 2029.

Share
Rapport Therapeutics Closes $172.5 Million Convertible Note Sale And $21.00-A-Share Stock Offering

Rapport Therapeutics, a clinical-stage biotech developing the epilepsy drug candidate RAP-219, closed a $172.5 million sale of convertible notes on Friday, alongside a $21.00-a-share stock offering and a private placement, an 8-K shows. The company believes the combined proceeds, plus existing cash, will fund operations through the end of 2029.

Three deals, one closing day

The public stock offering sold 8,333,334 shares at $21.00, plus pre-funded warrants for up to 1,190,476 shares at $20.999 each. Underwriters exercised their option in full on 1,428,571 additional shares. Rapport estimates net proceeds from the stock offering, including that option, at about $215.7 million.

The 2.25% convertible senior notes due 2032 came to $172,500,000 after underwriters took up their full over-allotment option, netting about $166.8 million. A concurrent private placement sold 1,428,571 shares at $21.00, for roughly $30.0 million. Morgan Stanley, Leerink Partners and Evercore were underwriters and placement agents.

The private-placement shares are unregistered. Rapport must file a resale registration statement for them by December 29, 2026.

How the notes convert

The notes convert at an initial price of about $26.7750 a share, roughly a 27.50% premium to the $21.00 offering price. Rapport has irrevocably chosen to settle conversions by delivering shares, so holders who convert receive stock rather than cash. Interest is payable semiannually starting June 1, 2027, and the notes mature on December 1, 2032.

Rapport can redeem the notes for cash on or after the later of December 6, 2030 and 60 days after topline results from its FOCUS 1 and FOCUS 2 trials in drug-resistant focal onset seizures and two planned bipolar mania trials. The stock must also have traded at or above 130% of the conversion price for at least 20 trading days in a 30-day window.

Cash and the runway

Rapport estimated cash, cash equivalents and short-term investments of about $395.0 million at September 30. The figure is preliminary and unaudited, and complete results will come in its quarterly report on Form 10-Q.

The company plans to use the proceeds mainly for ongoing and planned RAP-219 trials, other research and general corporate purposes. It said its estimate of funding through the end of 2029 rests on assumptions that may prove wrong, and it could use the money sooner.

Rapport has no products on the market. It focuses on small molecule medicines for neurological and psychiatric disorders, with RAP-219 studied in focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania.

The next dated step is the December 29, 2026 deadline for registering the private-placement shares for resale.

Sources

More on Rapport Therapeutics

All Rapport Therapeutics (RAPP) coverage →